
Fragility fractures, particularly hip, vertebral, and distal radius fractures, represent a major public health burden in ageing populations, carrying substantial mortality and loss of independence. Anti-resorptive and anabolic agents for osteoporosis treatment are central to secondary fracture prevention. Fracture liaison services and systematic post-fracture osteoporosis assessment are increasingly advocated by international guidelines.